-
CTI 2025 Expert Interview | Prof. Norbert Claude Gorin
We are pleased to share a featured interview from the Cellular Therapy and Immunotherapy Conference 2025 (CTI 2025) in Hangzhou, conducted in collaboration with Hematology Frontier. In this in-depth discussion,…
-
Professor Edmund Waller: Blocking VIP Signaling and Advancing CAR-T Therapy | Academic Exchange at Peking University Institute of Hematology
On November 2, 2025, Professors Michael R. Bishop, M.D. and Edmund Waller visited the Peking University Institute of Hematology for an academic exchange that included ward rounds, keynote lectures, and…
-
Professor Michael R. Bishop Visits Peking University Institute of Hematology: Advancing CAR-T Therapy and Strengthening Global Collaboration
On November 2, 2025, Professor Michael R. Bishop, M.D. visited the Peking University Institute of Hematology for clinical rounds, a keynote lecture, and focused exchanges on the future of cellular…
-
Dr. YishanYe: Continued Validation of the Advantages of Haploidentical Transplantation — Moving Toward an Era of “Timely Access to Optimal Donors for All” | 2025 International Cell & Immunotherapy Congress
To promote innovation in China’s cell therapy and immunotherapy fields, advance discussion of key scientific challenges, share the latest clinical research, and strengthen global collaboration and translational progress, the 2025 International Cell & Immunotherapy Congress (CTI 2025)—jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Immunology Society, and the Zhejiang Anti-Cancer Association—was held on November 13–16, 2025 in Hangzhou.
-
Uniting Global Wisdom, Strengthening the Fight Against Cancer — 2025 CCHIO CACA–UICC Special Session Review
The 2025 China Conference on Holistic Integrative Oncology (CCHIO), jointly hosted by the Chinese Anti-Cancer Association (CACA), the Organizing Committee of the Tengchong Scientists Forum, the World Association of Integrative Oncology (WAIO), and the China Academy of Integrative Medicine Development Strategy, was held in Kunming, Yunnan from November 6–9, 2025. On November 7, the CACA–UICC Special Session, co-organized by…
-
Blood Science Update|China Expert Consensus on mNGS for Diagnosing Infections in Hematological Disorders (2024)
The 2024 China Expert Consensus on metagenomic next-generation sequencing (mNGS) in hematological disorders, published in Blood Science, offers the first national guidance on how mNGS should be applied to infection diagnosis in this highly vulnerable population. Because hematological diseases and their treatments cause profound immunosuppression, infections remain a major cause of morbidity and mortality. Traditional microbiological tests (CMTs) frequently produce delayed or negative results, especially after antibiotic exposure. mNGS, which enables broad, unbiased pathogen detection, has therefore become an essential complementary tool.
-
Blood Science Update|A Prognostic Analysis of Acute Leukemia Patients With Prior CNS Involvement Undergoing Umbilical Cord Blood Transplantation
Background and Objective Prior CNS involvement may compromise post-transplant disease control because CNS-resident leukemic cells may persist despite conditioning and escape graft-versus-leukemia effects. Evidence regarding the impact of CNSL on UCBT outcomes remains limited. This…
-
Blood Science Update|A Prognostic Analysis of Acute Leukemia Patients With Prior CNS Involvement Undergoing Umbilical Cord Blood Transplantation
Published in Blood Science in 2025, the study led by Zichang Shen examines the impact of central nervous system leukemia (CNSL) on outcomes after umbilical cord blood transplantation (UCBT). CNSL remains a difficult manifestation of acute leukemia because leukemic cells within the CNS can evade systemic chemotherapy and drive relapse. Although allogeneic transplantation is the most effective curative approach for high-risk disease,…
Connecting Medical Expertise through Media